Vaccine (Recombinant protein vaccine) · Immune activation, directed at Streptococcus pneumoniae capsular polysaccharides (serotypes 1, 3, 4, 5, 6A, 6B, · developed by Wyeth Pharmaceuticals LLC
PCV20 is a 20-valent pneumococcal conjugate vaccine containing capsular polysaccharides from 20 Streptococcus pneumoniae serotypes, each conjugated to the CRM197 carrier protein. It is given intramuscularly to induce active immunity against pneumococcal disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07794748 | Phase 3 | Pneumococcal Disease | Active not recruiting | PFE |
| NCT07425392 | Phase 3 | Pneumococcal Vaccines | Active not recruiting | PCVX |
| NCT06151288 | Phase 1/2 | Pneumococcal Vaccines | Completed | PCVX |
| NCT05297578 | Phase 2 | Pneumococcal Vaccines | Completed | PCVX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
HealthyPneumococcal DiseasePneumococcal Vaccines
Updated Nov 15, 2026. Something wrong or missing? Report it on the PFE page.
See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PFE catalysts and pipeline →